This clinical trial investigated whether pimavanserin, an FDA-approved medication, could prevent the return of psychotic symptoms like hallucinations and delusions in dementia patients. The study enrolled 392 participants who had dementia-related psychosis and initially responded well to 12 weeks of pimavanserin treatment. Researchers then randomly assigned participants to continue taking either pimavanserin (at 20mg or 34mg doses) or switch to placebo to see which group experienced fewer relapses. Dementia-related psychosis affects up to 50% of people with dementia and significantly impacts quality of life for both patients and caregivers. The trial's relapse-prevention design helps determine optimal long-term treatment strategies for maintaining mental stability in vulnerable populations.
